Valuation: Beam Therapeutics Inc.

Market Cap 3.46B 3.04B 2.8B 2.62B 4.92B 327B 5.02B 33.66B 13.02B 162B 13.01B 12.73B 560B P/E 2026 *
-7.93x
P/E 2027 * -7.6x
Enterprise Value 2.61B 2.29B 2.11B 1.98B 3.7B 246B 3.78B 25.36B 9.81B 122B 9.8B 9.59B 422B EV / Sales 2026 *
35.7x
EV / Sales 2027 * 26.3x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
1 day+2.59%
1 week+1.96%
Current month+5.71%
1 month+6.13%
3 months+56.87%
6 months+24.41%
Current year+25.58%
1 week 32.79
Extreme 32.79
36.67
1 month 28.3
Extreme 28.3
36.88
Current year 21.63
Extreme 21.63
36.88
1 year 15.6
Extreme 15.6
36.88
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
138.52
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 01/01/2017
Director of Finance/CFO 48 19/12/2024
President 57 24/01/2020
Director TitleAgeSince
Director/Board Member 48 01/01/2017
Director/Board Member 75 01/05/2018
Director/Board Member 56 10/10/2019
Date Insider Type Main position Quantity % Market Cap.
06-17Fiscal year

Chairperson

71,010 0.0690%
06-03Free

Director

19,676 0.0191%
06-03Free

Director

19,676 0.0191%
Change 5-day change 1-year change 3-year change Capi.($)
+2.59%+1.96%+107.20%+5.23% 3.46B
+0.65%+7.19%-5.06%+2.56% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+25.31% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
-0.73%+7.84%+13.27%+21.17% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average +0.94%+8.42%+80.97%+100.70% 23.36B
Weighted average by Cap. +0.90%+8.61%+89.16%+129.27%

Financials

2026 *2027 *
Net sales 73.19M 64.17M 59.15M 55.38M 104M 6.9B 106M 711M 275M 3.41B 275M 269M 11.83B 87.27M 76.52M 70.54M 66.04M 124M 8.23B 126M 848M 328M 4.07B 328M 321M 14.11B
Net income -465M -408M -376M -352M -659M -43.84B -673M -4.51B -1.75B -21.67B -1.75B -1.71B -75.14B -521M -456M -421M -394M -739M -49.11B -754M -5.06B -1.96B -24.27B -1.95B -1.91B -84.16B
Net Debt -855M -749M -691M -647M -1.21B -80.61B -1.24B -8.3B -3.21B -39.84B -3.21B -3.14B -138B -1.17B -1.03B -947M -887M -1.66B -111B -1.7B -11.38B -4.4B -54.63B -4.4B -4.3B -189B
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
522
Date Price Change Volume
26/06/26 $34.81 +2.59% 4,788,375
25/06/26 $33.93 +0.09% 2,158,018
24/06/26 $33.90 +2.11% 3,037,805
23/06/26 $33.20 -6.56% 3,604,536
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
34.81USD
Average target price
51.07USD
Spread / Average Target
+46.70%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BEAM Stock